Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Rhea-AI Summary

Alpha Cognition (ACOG) has announced the pricing of its upsized public offering of 8,695,653 common shares at $5.75 per share, raising approximately $50 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to 1,184,592 additional shares. The offering is expected to close on November 13, 2024. ACOG will begin trading on Nasdaq on November 12, 2024. Proceeds will fund the commercialization of ZUNVEYL for Alzheimer's Disease, pipeline development, CMC activities, and working capital.

Positive

• FDA-approved drug ZUNVEYL for Alzheimer's Disease ready for commercialization
• $50 million capital raise strengthens balance sheet
• Uplisting to Nasdaq may increase stock visibility and liquidity
• Clear allocation of funds for product commercialization and R&D

Negative

• Significant shareholder dilution through 8.7M new shares offering
• Additional dilution possible through 1.18M share overallotment option

Insights

Financial Analyst

The $50 million upsized public offering and Nasdaq uplisting represents a significant milestone for Alpha Cognition. With shares priced at $5.75, this capital raise strengthens their balance sheet substantially for the commercialization of ZUNVEYL, their FDA-approved Alzheimer's treatment. The offering was notably upsized, indicating strong investor interest. The Nasdaq listing provides enhanced visibility and access to a broader investor base compared to their previous CSE listing.

The strategic allocation of funds towards commercialization, R&D pipeline and manufacturing demonstrates a well-structured approach to market entry. The 30-day over-allotment option for additional shares could potentially increase the raise by approximately $6.8 million. The timing aligns well with their commercial launch plans, providing important working capital for scaling operations.

Medical Research Analyst

The successful financing positions Alpha Cognition to execute the commercial launch of ZUNVEYL in the lucrative Alzheimer's Disease market. The FDA approval for mild-to-moderate Alzheimer's Disease represents a significant therapeutic opportunity, addressing a critical unmet need in neurodegenerative disorders. The company's commitment to further R&D pipeline development suggests potential for additional neurodegenerative disease treatments.

The emphasis on CMC activities indicates a focus on maintaining high manufacturing standards and scalability. This is important for consistent drug production and meeting potential market demand. The strong investor interest reflected in the upsized offering suggests confidence in both the commercial potential of ZUNVEYL and the company's broader neurodegenerative disease platform.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the pricing of its upsized public offering of 8,695,653 common shares at a public offering price of $5.75 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts, commissions, and estimated offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,184,592 common shares to cover over-allotments at the public offering price, less the underwriting discount. All of the common shares are being offered by the Company. The offering is expected to close on November 13, 2024, subject to the satisfaction of customary closing conditions.

The Company has received approval to list its common shares on the Nasdaq Capital Market under the symbol “ACOG” and is expected to begin trading on Nasdaq today, November 12, 2024.

The Company intends to use the proceeds towards the commercialization and launch of ZUNVEYL^TM in Alzheimer’s Disease, further research and development of its pipeline product candidates, continued commercial CMC activities (chemistry, manufacturing, and controls), and for working capital and general corporate purposes.

“This offering serves as a tremendous milestone for Alpha Cognition, as we begin the commercialization of our FDA-approved drug, ZUNVEYL, for the treatment of mild-to-moderate Alzheimer’s Disease,” said Michael McFadden, Chief Executive Officer and Director of the Company. "This financing puts our balance sheet in a position of meaningful strength and provides the necessary foundation for a successful commercial launch, with ample runway to scale over the next few years. We are thrilled to welcome a number of new, high-quality investors to our Nasdaq listing, who also see the benefits of ZUNVEYL and the exciting opportunity for our platform.”

Titan Partners Group, a division of American Capital Partners, is acting as Sole Bookrunner for the offering.

The securities were sold pursuant to a registration statement on Form S-1 (File No. 333-280196) relating to these securities and a related registration statement on Form S-1 MEF that became effective upon its filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended. The Offering is being made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained, when available, from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, or via email at prospectus@titanpartnersgrp.com or telephone at (929) 833-1246. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC's website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

Forward-looking Statements

This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential closing of the Offering, the use of proceeds of the Offering, receipt of regulatory and stock exchange approvals in connection with Offering and completion of the Nasdaq uplisting. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241112017064/en/

For further information:

Michael McFadden, CEO

Tel: 1-858-344-4375

info@alphacognition.com

Titan Partners Contact:

Tel: (929) 833-1246

info@titanpartnersgrp.com

Source: Alpha Cognition Inc.

FAQ

What is the price per share for Alpha Cognition's (ACOG) public offering in 2024?

Alpha Cognition priced its public offering at $5.75 per share.

How many shares is Alpha Cognition (ACOG) offering in its 2024 public offering?

Alpha Cognition is offering 8,695,653 common shares, with an additional 30-day option for underwriters to purchase up to 1,184,592 shares.

When will Alpha Cognition (ACOG) begin trading on Nasdaq?

Alpha Cognition is expected to begin trading on Nasdaq on November 12, 2024, under the symbol ACOG.

What will Alpha Cognition (ACOG) use the public offering proceeds for?

The proceeds will be used for ZUNVEYL commercialization in Alzheimer's Disease, pipeline product development, CMC activities, and working capital.